Empowered Patient Podcast Identification of Genetic Biomarker Leads to Effective Drug to Treat Alcohol Use Disorder with Tony Goodman Adial Pharmaceuticals
Tony Goodman is the Chief Operating Officer at Adial Pharmaceuticals, which is developing a personalized therapy for alcohol use disorder based on a genetic biomarker. This unique approach combines the therapeutic AD04 with the biomarker AG Plus to identify a specific AUD patient population that responds well to this drug. Insights from this work could potentially lead to a broader understanding of the genetic and neurobiological connection underlying addiction.
Tony explains, "What makes us unique is that we're out in front of where the current prevailing wisdom of science is going in the addiction space. There's a renewed interest in personalized medicine or genetics, the study of genetic biomarkers, and things of that sort in addiction. As you know, we've been doing this for a long time. And so I think the uniqueness comes into the fact that we've coupled a therapeutic with a genetic biomarker, in this case, known as AG Plus, which we believe can produce results for patients that have this specific genotype. And you may recall that there's a lot of individual variability in addiction, and particularly at AUD, you have gender and genetic differences. You have sort of history of genetic patient history, differences, environmental factors, comorbid conditions including major depression, and you have trauma."
"A lot of patients in the AUD space have a history of PTSD or negative experiences. There's a lot of variation in severity levels, which is something else we find unique about our program because we have stratified patients into less than ten drinks per drinking day and greater than ten drinks per drinking day. We know there is a difference in the responder analysis of the patients who fall into the less than ten drinks per drinking day. And a lot of theories have been postulated as to why that may be the case."
#Adial #AlcoholUseDisorder #AUD #HealthcareInnovations #AddictionTreatment #BiotechSolutions #GeneticBiomarkers #PrecisionMedicine